| Patent Number |
Title Of Patent |
Date Issued |
| RE39678 |
Meiosis regulating compounds |
June 5, 2007 |
| Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells. |
| RE38253 |
Composition for contraception |
September 16, 2003 |
| A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg of ethinylestradiol;and a gestagen selected from .[.0.25 to 0.30.]. .Iadd.2.5 to 3.0 .Iaddend.mg of drospirenone and .[.0.1 to 0.2.]. .Iad |
| RE37564 |
Composition for contraception |
February 26, 2002 |
| A combination product for oral contraception is disclosed comprising an estrogen selected from2.0 to 6.0 mg of 17.beta.-estradiol and0.020 mg of ethinylestradiol;and a gestagen selected from.[.0.25 to 0.30.]. .Iadd.2.5 to 3.0 .Iaddend.mg of drospirenone and.[.0.1 to 0.2.]. .Iadd.1 to 2 .Iadden |
| RE28690 |
17.alpha.-Ethinyl-18-methyl-19-nortestosterone esters |
January 20, 1976 |
| A therapeutic compound for inhibiting ovulation comprising a 17-ester of 17.alpha.-ethinyl-18-methyl-19-nortestosterone wherein the said 17-ester group is formed from an aliphatic carboxylic acid having from six to 11 carbon atoms in the ester residue..Iaddend. |
| D506256 |
Adapter for transfer of medical solution |
June 14, 2005 |
|
| D250123 |
Transport container for dangerous liquids |
October 31, 1978 |
|
| 7378404 |
8.beta.-hydrocarbyl-substituted estratrienes for use as selective estrogens |
May 27, 2008 |
| This invention describes the new 8.beta.-substituted estratrienes of general formula I in which R.sup.2, R.sup.3, R.sup.6, R.sup.6', R.sup.7, R.sup.7', R.sup.9, R.sup.11, R.sup.11', R.sup.12, R.sup.14, R.sup.15, R.sup.15', R.sup.16, R.sup.16', R.sup.17 and R.sup.17' have the meanings |
| 7345075 |
1,2 diarylbenzimidazoles and their pharmaceutical use |
March 18, 2008 |
| Benzimidazoles of general formula I ##STR00001## and the use of benzimidazole derivatives for the production of pharmaceutical agents for treatment and prophylaxis of diseases that are associated with a microglia activation are described. |
| 7335775 |
Effector conjugates, process for their production and their pharmaceutical use |
February 26, 2008 |
| Conjugates of epothilones and epothilone derivatives (as effectors) with suitable biomolecules (as recognition units) are described. Their production is carried out by the effectors being reacted with suitable linkers, and the compounds that are produced are conjugated to the recogni |
| 7335650 |
Composition |
February 26, 2008 |
| There is provided a pharmaceutical composition comprising (i) a compound of the formula ##STR00001## wherein: X is a hydrocarbyl ring having at least 4 atoms in the ring; K is a hydrocarbyl group; Rs is a sulphamate group; (ii) optionally admixed with a pharmaceutically acceptable c |
| 7329679 |
1,2 Diarylbenzimidazoles and their pharmaceutical use |
February 12, 2008 |
| Benzimidazoles of general formula I ##STR00001## and the use of benzimidazole derivatives for the production of pharmaceutical agents for treatment and prophylaxis of diseases that are associated with a microglia activation are described. |
| 7321044 |
Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the pro |
January 22, 2008 |
| The invention relates to intermediate products and a new process for the production of benzocycloheptene C. ##STR00001## The process for the production of its new intermediate products according to the invention starts from economical starting materials, provides the intermediate sta |
| 7317028 |
Cell differentiation inducer |
January 8, 2008 |
| The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermato |
| 7297702 |
Contraception method using competitive progesterone antagonists and novel compounds useful there |
November 20, 2007 |
| Competitive progesterone antagonists, including two novel steroids, viz., 11.beta.,19-[4-(cyanophenyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-h- ydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11.beta.,19-[4-(3-pyridinyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-h- ydroxyprop-1(Z)-en |
| 7223798 |
Lipoxin A.sub.4 analogs |
May 29, 2007 |
| This invention is directed to lipoxin A4 analogs of the following formula (II): ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also usef |
| 7220856 |
Substituted quinoline CCR5 receptor antagonists |
May 22, 2007 |
| The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b): ##STR00001## enantiomers, diastereomers, salts and solvates thereof wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.7 are as defined herein. The invention further includes a method of |
| 7211680 |
Vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their produ |
May 1, 2007 |
| Compounds of Formula I, ##STR00001## wherein Y.sub.1, Y.sub.2, R.sub.1 R.sub.6, Q and Z are as defined herein, are vitamin D derivatives. These compounds are useful for, e.g., the treatment hyperprolifierative diseases of the skin, tumor diseases and precancerous stages, auto-immune |
| 7211241 |
Cascade polymer complexes, process for their production and pharmaceutical agents containing sai |
May 1, 2007 |
| Described are new cascade polymer complexes, compositions containing them and use of the complexes in diagnosis and therapy, particularly for magnetic resonance imaging and computer tomography imaging. |
| 7208140 |
Trimeric macrocyclic substituted benzene derivatives |
April 24, 2007 |
| The metal complexes of general formula I ##STR00001## in which Hal stands for bromine or iodine and A.sup.1 and A.sup.2 have different meanings, are suitable as contrast media. |
| 7202263 |
N-heterocyclic derivatives as NOS inhibitors |
April 10, 2007 |
| N-Heterocyclic derivatives of the following formula: ##STR00001## where m, n, p, A.sup.1, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are described herein, as well as other N-heterocyclic derivatives, are useful as inhibitors of nitric oxide synthase. Pharmaceutical compositions containin |
| 7199268 |
Process for the production of dendritic trimesic acid triamides |
April 3, 2007 |
| A new process for the production of dendritic trimesic acid triamides is described. |
| 7199146 |
Imidazolidinedione analogs useful as anticoagulants and antithrombotics |
April 3, 2007 |
| A compound is disclosed, which is useful in treating a mammal having a disease-state characterized by thrombotic activity. The compound is of the following formula: ##STR00001## wherein A, B, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined herein or an isomer or isomeric mixture |
| 7176207 |
Platelet adenosine diphosphate receptor antagonists |
February 13, 2007 |
| Compounds of the following formula (I): ##STR00001## where A, a, b, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds |
| 7176013 |
Modified corin molecules having substitute activation sequences and uses thereof |
February 13, 2007 |
| This invention relates to novel modified corin molecules, or fragments or derivatives thereof, comprising a substitute activation sequence. The modified corin molecules are cleaved at the substitute activation sequence, thereby generating activated corin molecules, or fragments or de |
| 7166592 |
Nonsteroidal antiinflammatory agents |
January 23, 2007 |
| Compounds of Formula 1 ##STR00001## are useful in the treatment of inflammation. |
| 7148207 |
Oral fludara of high-purity formulation with quick release of active ingredient |
December 12, 2006 |
| This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants. |
| 7141566 |
Benzoxazine and benzothiazine derivatives and the use thereof in medicaments |
November 28, 2006 |
| The invention relates to compounds of formula (I), the tautomeric and isomeric forms and salts thereof, in addition to a method for production and use thereof in medicaments. ##STR00001## |
| 7138379 |
Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I |
November 21, 2006 |
| The present invention is directed towards a method of potentiating the anti-growth effects of type I interferon (IFN) on cells in a target cell population comprising increasing the number of functional IFNAR2c receptors on the surface of modified cells within the target cell populati |
| 7129254 |
Effector conjugates, process for their production and their pharmaceutical use |
October 31, 2006 |
| Conjugates of epothilones and epothilone derivatives (as effectors) with suitable biomolecules (as recognition units) are described. Their production is carried out by the effectors being reacted with suitable linkers, and the compounds that are produced are conjugated to the recogni |
| 7119082 |
11.beta.-long-chain-substituted 19-nor-17.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a |
October 10, 2006 |
| This invention relates to new 19-nor-17.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring with a long-chain substituent in 11.beta.-position of general formula II ##STR00001## in which R.sup.11 means a straight-chain alkyl radical with 6 to 17 carbon atoms, |
| 7115645 |
1,2 diarylbenzimidazoles and their pharmaceutical use |
October 3, 2006 |
| Benzimidazoles of general formula I ##STR00001## and the use of benzimidazole derivatives for the production of pharmaceutical agents for treatment and prophylaxis of diseases that are associated with a microglia activation are described. |
| 7105563 |
Indolinone derivatives and their use in treating disease-states such as cancer |
September 12, 2006 |
| Indolinone derivatives, such as compounds of the formula (I): ##STR00001## wherein A, m, n, R.sup.1, R.sup.2, R.sup.3, R.sup.5 and R.sup.6 are described herein, are disclosed herein as being useful in treating mammal having disease-states alleviated by the inhibition of PDK-1 activity |
| 7101880 |
Peptidic compounds as cysteine protease inhibitors |
September 5, 2006 |
| The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising |
| 7084142 |
Platelet adenosine diphosphate receptor antagonists |
August 1, 2006 |
| Compounds of the following formula: ##STR00001## where m, n, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as a |
| 7067667 |
Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors |
June 27, 2006 |
| 3,4-dihydroquinoline derivatives, a process for their production and their use in pharmaceutical agents. |
| 7056923 |
Platelet adenosine diphosphate receptor antagonists |
June 6, 2006 |
| Compounds of the following formula: ##STR00001## where m, n, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as a |
| 7053112 |
Imidazolidinedione analogs useful as anticoagulants and antithrombotics |
May 30, 2006 |
| A compound is disclosed, which is useful in treating a mammal having a disease-state characterized by thrombotic activity. The compound is of the following formula: ##STR00001## wherein A, B, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined herein or an isomer or isomeric mixt |
| 7033841 |
Process and compounds for use in detecting analytes by measurement of residual magnetism, and th |
April 25, 2006 |
| The invention relates to a process for quantitative detection of analytes in liquid and solid phases with the aid of binding remanence measurement, compounds that are suitable for this purpose, and their use in analytic chemistry. |
| 7026323 |
Platelet adenosine diphosphate receptor antagonists |
April 11, 2006 |
| Compounds of the following formula (I): ##STR00001## where a, b, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds |
| 7002022 |
N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF |
February 21, 2006 |
| Described are compunds of formula (I), wherein W is O or S; X is NR.sub.8; Y is CR.sub.9R.sub.10--(CH.sub.2)n wherein R.sub.9 and R.sub.10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO.sub.2; R.sub.2 is |
| 6995156 |
Platelet adenosine diphosphate receptor antagonists |
February 7, 2006 |
| Compounds of the following formula (I): ##STR00001## where a, b, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds |
| 6987101 |
Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
January 17, 2006 |
| A method for treating premenstrual dysphoric disorder comprises administering a therapeutically effective amount of a gestagen. Optionally, a natural or synthetic estrogen is also administered. In one embodiment, the gestagen and optional estrogen are administered during the luteal p |
| 6982259 |
N-heterocyclic derivatives as NOS inhibitors |
January 3, 2006 |
| N-Heterocyclic derivatives of the following formula: ##STR00001## where m, n, p, A.sup.1, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are described herein, as well as other N-heterocyclic derivatives, are useful as inhibitors of nitric oxide synthase. Pharmaceutical compositions containi |
| 6977258 |
Piperazine derivatives and their use as anti-inflammatory agents |
December 20, 2005 |
| This invention is directed to acyl piperazine derivatives of formula (Ia): ##STR1##wherein R.sup.1a, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are defined herein, which are useful as anti-inflammatory agents. This invention is also directed to other acyl piperazine derivatives, |
| 6972290 |
Piperazine derivatives and their use as anti-inflammatory agents |
December 6, 2005 |
| This invention is directed to acyl piperazine derivatives which are useful as anti-inflammatory agents. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat inflammatory disorders in humans. |
| 6966894 |
Syringes and injectors incorporating mechanical fluid agitation devices |
November 22, 2005 |
| A syringe for use with an injector includes a body comprising a distal discharge end, a plunger movably disposed within the body, and an agitation element disposed within the body between the plunger and the distal discharge end. A movement mechanism is operably associated with the i |
| 6962932 |
1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of phar |
November 8, 2005 |
| New benzimidazole derivatives are described, their production and their use for the production of pharmaceutical agents for treatment and prevention of diseases that are associated with a microglia activation and T-cell-mediated immunological diseases, as well as pharmaceutical prepa |
| 6956031 |
11.beta.-Substituted 19-nor-17-.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-l |
October 18, 2005 |
| This invention relates to new 19-nor-17.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring with a long-chain substituent in 11.beta.-position of general formula II ##STR1##in which R.sup.11 is a long-chain alkyl radical that has a nitrogen atom that can b |
| 6894038 |
Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases |
May 17, 2005 |
| The invention relates to the use of esters of estriol, for example, an estriol 3,17-dipropionate or an estriol 3,17-dihexanoate, for the treatment of autoimmune diseases, such as multiple sclerosis (MS). |
| 6878720 |
VEGF receptor tyrosine kinase inhibitors |
April 12, 2005 |
| Described are compunds of formula (I), wherein W is O or S; X is NR.sub.8 ; Y is CR.sub.9 R.sub.10 --(CH.sub.2)n wherein R.sub.9 and R.sub.10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO.sub.2 ; R.sub. |
